Applicants wish to thank the Examiner for pointing out the obvious error in the formulas describing the branched lipophilic moieties of compounds such as that represented by formula (II) on page 15 of the specification. In the corrected formulas following, the second carbon properly indicates the single hydrogen of the glycerol moiety from which the lipophilic substituents are attached:

$$-O-CH_2-C\underline{H}(O-C(O)-R_6)-CH_2(O-C(O)-R_7),$$

 $-O-CH_2-C\underline{H}(OR_6)-CH_2(OR_7),$
 $-O-CH_2-C\underline{H}(R_6)-CH_2(R_7).$

Amendments have been made to include inadvertently omitted indications of the positively charged nitrogens of certain of the nitrogen based substituents. This amendment merely clarifies the understood cationic nature of the amino sugar at useful pH, i.e. a pH at which the amino sugar has a cationic nature able to interact with anions such as polynucleotides.

Consistent amendments throughout the specification are respectfully requested as follows:

IN THE SPECIFICATION

Please delete the third full paragraph on page 5, starting from line 27 and ending with line 10 of page 6 with the following replacement paragraph:

(X)

In a first aspect, the invention features a compound comprising a glycosyl moiety having a nitrogen-based substituent linked to a carbon atom within the glycosyl moiety, where the nitrogen-based substituent is selected from the group

.


consisting of $-NH_2$, $-N^+(CH_3)_3$, $-(CH_2)_n-N^+(R_{10})_3$, and $-NH-C(N^+H_2)-NH_2$, and where substituents linked to other carbon atoms within the glycosyl moiety are selected from the group consisting of hydrogen, -alkyl, -O-alkyl,

- -O-C(O)-alkyl, $-O-CH_2-CH(O-C(O)-R_6)-CH_2(O-C(O)-R_7)$,
- $-O-CH_2-CH(OR_6)-CH_2(OR_7), -O-CH_2-CH(R_6)-CH_2(R_7),$
- $-O-(CH_2)_m$ -cholesterol, polyethylene glycol, $-O-(CH_2)_n-N^+(R_8)_3$, $-NH_2$,
- $-N^{+}(CH_3)_3$, $-(CH_2)_n-N^{+}(R_9)_3$, $-(CH_2)-OR_{10}$ where R_6 , R_7 , R_8 , R_9 , and R_{10} are independently selected from the group consisting of hydrogen, methyl, and alkyl, and where m is selected from the group consisting of 0, 1, 2, 3, 4, and 5, and where n is selected from the group consisting of 1, 2, 3, 4, and 5.

Not

2) Please delete the second full paragraph on page 8, starting from line 8 and ending with line 2 of page with the following replacement paragraph:

In another aspect, the invention features a compound having a structure set forth in formula I:



{I}

where (a) R_1 and R_1' are independently selected from the group consisting of hydrogen, -OH, $-OCH_3$, -alkyl, -O-alkyl, -O-C(O)-alkyl, $-O-CH_2-CH(O-C(O)-R_6)-CH_2(O-C(O)-R_7)$, $-O-CH_2-CH(OR_6)-CH_2(OR_7)$, $-O-CH_2-CH(R_6)-CH_2(R_7)$, $-O-(CH_2)_m$ -cholesterol, polyethylene glycol, $-O-(CH_2)_n-N^+(R_8)_3$, $-NH_2$, $-N^+(CH_3)_3$, and $-(CH_2)_n-N^+(R_9)_3$, where R_6 , R_7 , R_8 , and R_9 are independently selected from the group consisting of hydrogen, methyl, and alkyl, and where m is selected from the group consisting of 0, 1, 2, 3, 4, and 5, and where n is selected from the group consisting of 1, 2, 3, 4, and 5; (b) R_2 and R_2' are independently selected from the group consisting $-NH_2$, $-N^+(CH_3)_3$,

 $-(CH_2)_n-N^+(R_{11})_3$, and $-NH-C(N^+H_2)-NH_2$, wherein R_{11} is selected from the group consisting of hydrogen, methyl, and alkyl; and (c) R_3 , R_3' , R_4 , R_4' , R_5 , and R_5' are independently selected from the group consisting of hydrogen, -OH, $-OCH_3$, -alkyl, -O-alkyl, -O-C(O)-alkyl, $-O-CH_2-CH(O-C(O)-R_6)-CH_2(O-C(O)-R_7)$, $-O-CH_2-CH(OR_6)-CH_2(OR_7)$, $-O-CH_2-CH(OR_6)-CH_2(OR_7)$, $-O-(CH_2)_m$ -cholesterol, polyethylene glycol, $-O-(CH_2)_n-N^+(R_8)_3$, $-NH_2$, $-N^+(CH_3)_3$, and $-(CH_2)_n-N^+(R_9)_3$, where R_6 , R_7 , R_8 , and R_9 , are independently selected from the group consisting of hydrogen, methyl, and alkyl, and where m is selected from the group consisting of 0, 1, 2, 3, 4, and 5, and where n is selected from the group consisting of 1, 2, 3, 4, and 5, provided that R_5' is not $-CH_2-O-C(O)-(CH_2)_1ACH_3$ when R_3' and R_4' are -OH and R_2' is $-NH_2$ and R_1' is $-OCH_3$, and provided that R_5' is not $-CH_2-O-C(O)-(CH_2)_pCH_3$, where p is selected from the group consisting of 10, 12, 14, or 16, when R_3' is identical to R_5' and R_4' is -OH and R_2' is $-NH_2$ and R_1' is $-OCH_3$.

3) Please delete the fourth full paragraph on page 12, starting from line 27 and ending with line 30 with the following replacement paragraph:

B3

In yet another preferred embodiment, the invention relates to the compound of formula (I), where R_1 and R_1' are independently selected from the group consisting of hydrogen, $-OCH_3$, -alkyl, -O-alkyl, -O-C(O)-alkyl, $-O-CH_2-CH(alkyl)-CH_2(alkyl)$, $-O-CH_2-CH(O-alkyl)-CH_2(O-alkyl)$, $-O-CH_2-CH(O-C(O)-alkyl)-CH_2(O-C(O)-alkyl)$, $-O-(CH_2)_m$ -cholesterol, polyethylene glycol, $-O-(CH_2)_n-NH_2$, and $-O-(CH_2)_n-N^+(CH_3)_3$, where m is selected from the group consisting of 0, 1, 2, 3, 4, and 5, and where n is selected from the group consisting of 1, 2, 3, 4, and 5.

4) Please delete the third full paragraph on page 16, starting from line 16 and ending with page 17, line 5, with the following replacement paragraph:

Thus in another aspect, the invention features a compound for delivering one or more macromolecules into cells, comprising: (a) a compound comprising a glycosyl moiety having a nitrogen-based substituent linked to a carbon atom within the glycosyl moiety, where the nitrogen-based substituent is selected from the group consisting of $-NH_2$, $-N^+(CH_3)_3$, $-(CH_2)_n-N^+(R_{10})_3$, and $-NH-C(N^+H_2)-NH_2$, and where substituents linked to other carbon atoms within the glycosyl moiety are selected from the group consisting of hydrogen, -alkyl, -O-alkyl, -O-C(O-alkyl, -O-CH $_2-$ CH(O-C(O-C(O-R $_6)-$ CH $_2$ (O-C(O-R $_7)$, -O-CH $_2-$ CH(O-C(O-CH $_2$), -O-CH $_2-$ CH(O-C(O-CH $_2$), -O-CH $_2-$ CH(O-CH $_3$), -O-CH $_3-$ CH(O-CH $_3$), -O-CH $_3-$ CH(O-CH $_3-$ CH $_3-$ CH


5) Please delete the first full paragraph on page 17, starting from line 6 and ending 9 1996, 20 with line 33 with the following replacement paragraph:

In another aspect, the invention features a composition for delivering one or more macromolecules into cells, comprising: (a) a compound having a structure set forth in formula (I), where (i) R_1 and R_1 ' are independently selected from the group consisting of hydrogen, -OH, $-OCH_3$, -alkyl, -O-alkyl, -O-C(O)-alkyl, $-O-CH_2-CH(O-C(O)-R_6)-CH_2(O-C(O)-R_7)$, $-O-CH_2-CH(OR_6)-CH_2(OR_7)$, $-O-CH_2-CH(R_6)-CH_2(R_7)$, $-O-(CH_2)_m$ -cholesterol, $-O-(CH_2)_n-N^+(R_8)_3$, $-NH_2$, $-N^+(CH_3)_3$, $-(CH_2)-N^+(R_9)_3$, and $-(CH_2)-OR_{10}$, where R_6 , R_7 , R_8 , R_9 , and R_{10} are independently selected from the group consisting of hydrogen, methyl, and alkyl, and





where m is selected from the group consisting of 0, 1, 2, 3, 4, and 5, and where n is selected from the group consisting of 1, 2, 3, 4, and 5; (ii) R_2 and R_2 ' are independently selected from the group consisting of hydrogen, $-NH_2$, $-N^+(CH_3)_3$, $-(CH_2)_n-N^+(R_{10})_3$, and $-NH-C(N^+H_2)-NH_2$, wherein R_{10} is selected from the group consisting of hydrogen, methyl, and alkyl; and (iii) R_3 , R_3 , R_4 , R_4 ', R_5 , and R_5 ' are independently selected from the group consisting of hydrogen, -OH, $-OCH_3$, -alkyl, -O-alkyl, -O-C(O)-alkyl, -O-CH₂-CH(O-C(O)- R_6)-CH₂(O-C(O)- R_7), -O-CH₂-CH(OR_6)-CH₂(OR_7), -O-CH₂-CH(OR_6)-CH₂(OR_7), -O-CH₂-CH(OR_8)-CH₂(OR_7), -O-CH₂-CH(OR_8)-CH₂(OR_8), and OR_8 , OR_8 , OR



In yet another preferred embodiment, the invention relates to the

oncid oncid

7) Please delete the third full paragraph on page 28, starting from line 12 and ending with page 29, line 6 with the following replacement paragraph:

In yet another aspect, the invention features a method for synthesizing a compound of the invention, comprising the steps of: (a) reacting a first reactant of formula (V):

the compound of the invention.

group consisting of hydrogen, halogen atom, and an activatable moiety: X₂ and X₃ are independently selected from the group consisting of a protecting moiety, hydrogen, halogen, or any activatable moiety; and where X₄, X₄′, X₅, X₅′, X₆, and X₆′ are independently selected from the group consisting of hydrogen, –O–acetyl, –OH, –CH₂–O–acetyl, –CH₂–OH, and –O–alkyl; where the second reactant is selected from the group consisting of HOCH₃, HO–alkyl, HO–C(O)–alkyl, HO–CH₂–CH(O–C(O)–R₆)–CH₂(O–C(O)–R₇), HO–CH₂–CH(OR₆)–CH₂(OR₇), HO–CH₂–CH(OR₆)–CH₂(OR₇), HO–(CH₂)_m–cholesterol, HO–(CH₂)_n–N(R₈)₃, where R₆, R₇, and R₈ are independently selected from the group consisting of hydrogen, methyl, and alkyl, and where m is selected from the group consisting of 0, 1, 2, 3, 4, and 5, and where n is selected from the group consisting of 1, 2, 3, 4,

With a second reactant, where X_1 and X_1 ' are independently selected from the

and 5; (b) reacting the product of step (a) with a reducing agent; and (c) purifying